PL3475425T3 - Leczenie niealkoholowego stłuszczeniowego zapalenia wątroby (nash) - Google Patents
Leczenie niealkoholowego stłuszczeniowego zapalenia wątroby (nash)Info
- Publication number
- PL3475425T3 PL3475425T3 PL17732939T PL17732939T PL3475425T3 PL 3475425 T3 PL3475425 T3 PL 3475425T3 PL 17732939 T PL17732939 T PL 17732939T PL 17732939 T PL17732939 T PL 17732939T PL 3475425 T3 PL3475425 T3 PL 3475425T3
- Authority
- PL
- Poland
- Prior art keywords
- nash
- treatments
- alcoholic steatohepatitis
- steatohepatitis
- alcoholic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Detergent Compositions (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16176755.3A EP3263705A1 (en) | 2016-06-28 | 2016-06-28 | Treatments of non-alcoholic steatohepatitis (nash) |
| PCT/EP2017/066025 WO2018002155A1 (en) | 2016-06-28 | 2017-06-28 | Treatments of non-alcoholic steatohepatitis (nash) |
| EP17732939.8A EP3475425B1 (en) | 2016-06-28 | 2017-06-28 | Treatments of non-alcoholic steatohepatitis (nash) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3475425T3 true PL3475425T3 (pl) | 2022-01-17 |
Family
ID=56296569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17732939T PL3475425T3 (pl) | 2016-06-28 | 2017-06-28 | Leczenie niealkoholowego stłuszczeniowego zapalenia wątroby (nash) |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11052102B2 (pl) |
| EP (3) | EP3263705A1 (pl) |
| JP (3) | JP7165058B2 (pl) |
| CY (1) | CY1124611T1 (pl) |
| ES (1) | ES2894914T3 (pl) |
| HR (1) | HRP20211727T1 (pl) |
| HU (1) | HUE056986T2 (pl) |
| LT (1) | LT3475425T (pl) |
| PL (1) | PL3475425T3 (pl) |
| PT (1) | PT3475425T (pl) |
| RS (1) | RS62622B1 (pl) |
| SI (1) | SI3475425T1 (pl) |
| SM (1) | SMT202100654T1 (pl) |
| WO (1) | WO2018002155A1 (pl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3785731A1 (en) * | 2019-08-28 | 2021-03-03 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Treating non-alcoholic steatohepatitis (nash) and hepatocellular carcinoma (hcc) with compounds binding the ectodomain of platelet glycoprotein ib (gpib) alpha |
| CN110859838A (zh) * | 2019-12-19 | 2020-03-06 | 南京市第一医院 | 氯吡格雷在制备预防或治疗非酒精性脂肪肝的药物中的应用 |
| WO2026057679A1 (en) * | 2024-09-11 | 2026-03-19 | Institut National de la Santé et de la Recherche Médicale | Inhibitor of rab30 for use in a method of treatment of metabolic dysfunction-associated steatotic liver disease (masld) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102006045550A1 (de) * | 2006-09-25 | 2008-04-03 | Dade Behring Marburg Gmbh | Verfahren zur Herstellung von agglutionationsfähigen Thrombozytenfragmenten und deren Verwendung |
| AR067446A1 (es) * | 2007-07-11 | 2009-10-14 | Otsuka Pharma Co Ltd | Un medicamento para tratar higado graso que comprende cilostazol |
| US20110082119A1 (en) * | 2008-06-13 | 2011-04-07 | Takashi Yano | Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis |
-
2016
- 2016-06-28 EP EP16176755.3A patent/EP3263705A1/en not_active Withdrawn
-
2017
- 2017-06-28 EP EP17732939.8A patent/EP3475425B1/en active Active
- 2017-06-28 LT LTEPPCT/EP2017/066025T patent/LT3475425T/lt unknown
- 2017-06-28 US US16/307,643 patent/US11052102B2/en active Active
- 2017-06-28 RS RS20211401A patent/RS62622B1/sr unknown
- 2017-06-28 PL PL17732939T patent/PL3475425T3/pl unknown
- 2017-06-28 SM SM20210654T patent/SMT202100654T1/it unknown
- 2017-06-28 HR HRP20211727TT patent/HRP20211727T1/hr unknown
- 2017-06-28 SI SI201730937T patent/SI3475425T1/sl unknown
- 2017-06-28 HU HUE17732939A patent/HUE056986T2/hu unknown
- 2017-06-28 JP JP2018566469A patent/JP7165058B2/ja active Active
- 2017-06-28 WO PCT/EP2017/066025 patent/WO2018002155A1/en not_active Ceased
- 2017-06-28 ES ES17732939T patent/ES2894914T3/es active Active
- 2017-06-28 EP EP21181633.5A patent/EP3913057A1/en not_active Withdrawn
- 2017-06-28 PT PT17732939T patent/PT3475425T/pt unknown
-
2021
- 2021-03-31 US US17/218,682 patent/US11806361B2/en active Active
- 2021-10-19 CY CY20211100910T patent/CY1124611T1/el unknown
-
2022
- 2022-10-20 JP JP2022168271A patent/JP7441921B2/ja active Active
-
2023
- 2023-09-28 US US18/374,023 patent/US20240024349A1/en active Pending
-
2024
- 2024-02-19 JP JP2024022767A patent/JP7672526B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20210213042A1 (en) | 2021-07-15 |
| US20240024349A1 (en) | 2024-01-25 |
| JP7441921B2 (ja) | 2024-03-01 |
| ES2894914T3 (es) | 2022-02-16 |
| JP7672526B2 (ja) | 2025-05-07 |
| US20190262379A1 (en) | 2019-08-29 |
| JP2024065114A (ja) | 2024-05-14 |
| CY1124611T1 (el) | 2022-07-22 |
| LT3475425T (lt) | 2021-11-10 |
| JP7165058B2 (ja) | 2022-11-02 |
| HUE056986T2 (hu) | 2022-04-28 |
| EP3263705A1 (en) | 2018-01-03 |
| US11052102B2 (en) | 2021-07-06 |
| JP2019524659A (ja) | 2019-09-05 |
| PT3475425T (pt) | 2021-10-26 |
| EP3475425B1 (en) | 2021-08-25 |
| EP3475425A1 (en) | 2019-05-01 |
| SI3475425T1 (sl) | 2021-12-31 |
| EP3913057A1 (en) | 2021-11-24 |
| US11806361B2 (en) | 2023-11-07 |
| JP2023002696A (ja) | 2023-01-10 |
| SMT202100654T1 (it) | 2022-01-10 |
| RS62622B1 (sr) | 2021-12-31 |
| HRP20211727T1 (hr) | 2022-02-18 |
| WO2018002155A1 (en) | 2018-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL248193B (en) | Compositions for use in treating nafld and nash | |
| ZA201807083B (en) | Non-invasive diagnostic of non-alcoholic steatohepatitis | |
| EP3445385A4 (en) | THERAPEUTIC GOALS INVOLVED IN THE PROGRESSION OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) | |
| SG11201507288UA (en) | Compositions and methods for treating non-alcoholic steatohepatitis | |
| ZA201706257B (en) | Treatment of wood | |
| SG11201609652RA (en) | Treatment of polybacterials infections | |
| LT3458052T (lt) | Vėžio kombinuotas gydymas | |
| ZA201902090B (en) | Combination treatments comprising administration of imidazopyrazinones | |
| IL267647A (en) | Combined treatment of non-alcoholic steatohepatitis (nash) and liver fibrosis | |
| IL263835A (en) | Exosome-guided treatment of cancer | |
| HUS2400045I1 (hu) | Delgocitinib alkalmazása krónikus kézekcéma kezelésére | |
| IL271236A (en) | Licofligozin for the treatment of non-alcoholic steatohepatitis | |
| EP3624800A4 (en) | TREATMENT OF HEPATOCELLULAR CARCINOMA | |
| SMT202100654T1 (it) | Trattamenti della steatoepatite non alcolica (nash) | |
| GB2548491B (en) | Treatment of fluids | |
| SMT202100037T1 (it) | Trattamento dell'emicrania con acetil-leucina | |
| EP3139911A4 (en) | Method of treating advanced non-alcoholic steatohepatitis | |
| IL278077A (en) | A treatment method for non-alcoholic steatohepatitis, NASH | |
| IL274770A (en) | Anti-huTNFR1 therapy in non-alcoholic steatohepatitis | |
| HK40017104A (en) | Licofligozin for the treatment of non-alcoholic steatohepatitis | |
| HK40035976A (en) | Anti-hutnfr1 therapy of nonalcoholic steatohepatitis | |
| HK40001613A (en) | Use of sgc stimulators for the treatment of nonalcoholic steatohepatitis (nash) | |
| GB201622214D0 (en) | treatment of cancer | |
| GB201523018D0 (en) | The traditional chinese medicine combination for the treatment of prostate | |
| GB201604621D0 (en) | Treatment of cancer |